Emerging PSA-based tests to improve screening
Bryant, Richard J. and Lilja, Hans LU
(2014)
In Urologic Clinics of North America
41(2).
p.267-276
- Abstract
This article updates advances in prostate cancer screening based on prostate-specific antigen, its derivatives, and human kallikrein markers. Many men are diagnosed with indolent disease not requiring treatment. Although there is evidence of a survival benefit from screening, the numbers needed to screen and treat remain high. There is risk of exposing men to the side effects of treatment for nonthreatening disease. A screening test is needed with sufficiently good performance characteristics to detect disease at an early stage so treatment may be offered with curative intent, while reducing the number of negative or unnecessary biopsies.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5ede1c53-6830-4bcc-9a4c-df42d2f3a6d1
- author
- Bryant, Richard J.
and Lilja, Hans
LU
- publishing date
- 2014-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Detection, Kallikreins, Prostate cancer, PSA, Screening
- in
- Urologic Clinics of North America
- volume
- 41
- issue
- 2
- pages
- 267 - 276
- publisher
- W.B. Saunders
- external identifiers
-
- scopus:84898484195
- pmid:24725489
- ISSN
- 0094-0143
- DOI
- 10.1016/j.ucl.2014.01.003
- language
- English
- LU publication?
- no
- id
- 5ede1c53-6830-4bcc-9a4c-df42d2f3a6d1
- date added to LUP
- 2022-12-06 14:26:08
- date last changed
- 2024-01-03 21:32:44
@article{5ede1c53-6830-4bcc-9a4c-df42d2f3a6d1,
abstract = {{<p>This article updates advances in prostate cancer screening based on prostate-specific antigen, its derivatives, and human kallikrein markers. Many men are diagnosed with indolent disease not requiring treatment. Although there is evidence of a survival benefit from screening, the numbers needed to screen and treat remain high. There is risk of exposing men to the side effects of treatment for nonthreatening disease. A screening test is needed with sufficiently good performance characteristics to detect disease at an early stage so treatment may be offered with curative intent, while reducing the number of negative or unnecessary biopsies.</p>}},
author = {{Bryant, Richard J. and Lilja, Hans}},
issn = {{0094-0143}},
keywords = {{Detection; Kallikreins; Prostate cancer; PSA; Screening}},
language = {{eng}},
number = {{2}},
pages = {{267--276}},
publisher = {{W.B. Saunders}},
series = {{Urologic Clinics of North America}},
title = {{Emerging PSA-based tests to improve screening}},
url = {{http://dx.doi.org/10.1016/j.ucl.2014.01.003}},
doi = {{10.1016/j.ucl.2014.01.003}},
volume = {{41}},
year = {{2014}},
}